The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev. 27, 179–192 (2008). Article CAS PubMed Google Scholar Mohi, M. G. & Neel, B. G. The role of Shp2 (PTPN11) in cancer. Curr. Opin. Genet. Dev. 17, 23–30 (2007). Article CAS PubMed Google Scholar ...
The Role of SHP2 in Regulating Fibroblast Senescence and HER2-Positive Breast CancerOncology.Src-homology-2 domain-containing phosphatase 2 (SHP2), encoded by the PTPN11 gene, is highly conserved across metazoans. SHP2 contains two SH2 domains, a protein-tyrosine phosphatase (PTP) domain and a...
et al. Overcoming resistance to dual innate immune and MEK inhibition downstream of KRAS. Cancer Cell 34, 439–452.e436 (2018). CAS PubMed PubMed Central Google Scholar Wong, G. S. et al. Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. ...
3 NS mutations can arise in several different genes but mutations in PTPN11 [MIM 176876], the gene encoding the protein tyrosine phosphatase nonreceptor type 11 (SHP-2), are the most frequent contributors. PTPN11 is expressed ubiquitously and plays an important role in animal development.4, 5,...
2. Tumor growth inhibition 3. Promotion of cell death 4. Reduction in inflammation 5. Inhibition of invasion and metastasis 6. Inhibition of the generation of vasculogenic mimicry 7. Others 8. Toxicity of RPS 9. Conclusions Data availability statement Funding Ethics statement CRediT authorship contr...
Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels. Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in approximately 40% of all CRC cases; its mutations result in constitutive activati
SHP2 tyrosine phosphatase (SH2 domain containing phosphatase 2, also known as PTPN11) has recently emerged as a key player in cell proliferation and immunity, providing an attractive therapeutic target for cancer. SHP2 activity is regulated by autoinhibition, unlocked by recruitment to specific pTyr...
[002] [002] The present invention relates to compositions and methods for the treatment of diseases or disorders (e.g., cancer) with SHP2 protein tyrosine phosphatase inhibitors, alone and in combination with other therapeutic agents such as an inhibitor of the pathway RAS (for example, a ...
Molecular mechanism for the Shp-2 tyrosine phosphatase function in promoting growth factor stimulation of Erk activity. Mol. Cell. Biol. 20, 1526–1536 (2000). CAS PubMed PubMed Central Google Scholar Tartaglia, M. et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2,...
The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.